Meet the Team: Andrew Ward
If you missed the recent news, Evaluate recently acquired J+D Forecasting, a provider of brilliant forecasting solutions to pharma and biotech companies. Andrew Ward has been with the J+D team for almost 10 years as Head of Implementation team, ensuring that the team is able to meet the ever-evolving needs of their customers. I grabbed […]
Orphan Drug Report 2024: Slowdown a Sign of Success
Hot-off-the-press, Evaluate has just released its latest annual deep dive into the world of orphan drugs and rare diseases. I had the opportunity to preview the content and make the case for why it is essential biopharma reading below. And while I have your attention, you can grab your complimentary copy of Orphan Drug Report […]
US Health Systems: A Driving Force for Digital Health
The US Healthcare system is a vast, unwieldy beast that requires significant navigation by any company in the healthcare space. Whether you’re a Big Pharma, a small biotech or an innovative digital health developer, access to this market (and its payers) is likely to be make or break for your business. This, in a nutshell, […]
Next Generation Dealmaking with Evaluate and Inpart
Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need regular topping up to ensure companies can deliver long-term growth in the face of new competition, and loss of exclusivity. At Evaluate, we work closely […]
Meet the Evaluate Team: Markella Kordoyanni
Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay on top of the latest developments and are able to deliver timely insights to their stakeholders. I caught up with Markella to learn about what […]
Competitive Intelligence Insights: Cell & Gene Therapy
The number of cell and gene therapy (C>)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market potential and the breadth of applicability across indications. For competitive intelligence teams tasked with staying on top of this complex and dynamic market, there is […]
In Case You Missed It: Three Things We Learned in Our 2024 Preview Webinar
Our focus was on the 2024 Preview, our annual report that looks at the top drugs, companies, potential launches and much more for the year ahead. In the webinar, our team talked through some of the highlights and discussed some of the stories behind the data, with a view to what it means for pharma […]
Sneak Peek at Our 2024 Preview Webinar
Fortunately, the annual Preview report that we publish at Evaluate is based on our consensus forecasting data. While that doesn’t guarantee accuracy – in the current market, guarantees are hard to come by – it does mean that the insight we share is based on some pretty solid data. The 2024 Preview report was published […]
Competitive Intelligence and the Quest for the Single Source of Truth
What’s in your competitor’s pipeline? How are their trials progressing? Who is on the cusp of a merger that will increase their funding and how will this impact your business? Continuous monitoring of the market landscape is the bread and butter of a CI professional and you can’t afford to miss anything that may impact […]
Knowledge and Insights: The Power of Real-World Data
Buzzwords in the life sciences industry – there are many: Artificial Intelligence (AI), Gen AI, Machine Learning (ML), digital health, and real-world data (RWD)/real world evidence (RWE). All are vast, complex areas with notable potential to impact our clients and the industry overall – across the continuum of the product lifecycle, spanning clinical and commercial […]
